PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 04: Articles 1501-2000 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. Emergency contraception.
  2. Emergency contraception.
  3. Emergency contraception: a pilot study by school nurses.
  4. Emergency contraception: does it cause a decline in contraceptive use?
  5. Emergency contraception: the journey so far. Review.
  6. Emergency contraception: the right questions?
  7. Epididymis as a target for contraception.
  8. Establishing integrated family planning / reproductive health preservice and inservice national clinical training systems in Turkey.
  9. Estimating the efficacy of emergency contraception [letter]
  10. Estimating the efficacy of emergency contraception. Reply of the authors [letter]
  11. Estrogen-containing oral contraceptives are allowable in young women with factor V Leiden heterozygosity without a history of thrombosis.
  12. Evaluation of the institutionalization of family planning / reproductive health inservice training in Bolivia. [Evaluación de la institucionalización de la planificación familiar y la capacitación en servicio sobre salud reproductiva en Bolivia.]
  13. Evra -- a patch on oral contraception?
  14. Exploring contraceptive pill taking among Hispanic women in the United States.
  15. Extended-use contraception offers revolution in reproductive choices.
  16. Extent of follow up care received by the family planning acceptors in rural areas of Dharwad district, Karnataka.
  17. Extrauterine translocated contraceptive device: a presentation of five cases and revisit of the enigmatic isues of iatrogenic perforation and migration.
  18. Factors influencing the use of contraception in an urban slum in Karachi, Pakistan.
  19. False risk attribution results in misleading assessment of the relationship between suppression of ovulation and the effectiveness of the Yuzpe regimen for emergency contraception [letter]
  20. False risk attribution results in misleading assessment of the relationship between suppression of ovulation and the effectiveness of the Yuzpe regimen for emergency contraception. Response to letter from Rafael T. Mikolajczyk and Joseph B. Stanford [letter]
  21. Family planning / HIV integration: technical guidance for USAID-supported field programs.
  22. Family planning a potential strategy for development in Rwanda.
  23. Family planning adoption in Jharkhand: an insight from two rounds of National Family Health Survey.
  24. Family planning and the campaigns against smoking and obesity.
  25. Family planning cited for counseling efforts.
  26. Family planning impact evaluation: the evolution of techniques.
  27. Family planning perspectives in Swedish community.
  28. Family planning programme in Punjab: a recent assessment of sterilisation beds scheme.
  29. Family planning seen as food crisis remedy.
  30. Family planning, gender differences and infant mortality: evidence from Uttar Pradesh, India.
  31. Fertility and contraception during the demographic transition: qualitative and quantitative approaches.
  32. Fertility and mortality decline in Nicaragua; contraceptive use increases.
  33. FFPRHC guidance: emergency contraception (April 2003)
  34. Follow-up of performance by pharmacy agents trained in contraceptive technology between 1998 and 2001 in Benin. [Suivi des performances d'employés de pharmacie formés aux technologies contraceptives entre 1998 et 2001 au Bénin.]
  35. Frequency of bacterial vaginosis among women attending for intrauterine device insertion at an inner-city family planning clinic.
  36. The gendered nature of contraception in France: Neo-Malthusianism, 1900-1920.
  37. Genital mycoplasmas in women attending a family planning clinic in Guiné-Bissau and their susceptibility to antimicrobial agents. [Prévalence des mycoplasmes génitaux chez des femmes fréquentant une clinique de planification familiale en Guinée-Bissau et leur susceptibilité aux agents antimicrobiens.]
  38. Global gag rule revisited: HIV / AIDS initiative out, family planning still in.
  39. In good conscience: the legal trend to include prescription contraceptives in employer insurance plans and Catholic charities', "conscience clause" objection.
  40. Graduating El Salvador from contraceptive assistance. [El Salvador se gradúa en atención anticonceptiva.]
  41. Health personnel perceptions about emergency contraception in primary health-care centers.
  42. Hormonal contraception and cervical cancer [letter]
  43. Hormonal contraception and STIs. Researchers continue to investigate a possible relationship.
  44. Hormonal contraception without estrogens.
  45. Hormonal contraception, immune responses, and pelvic inflammatory disease [letter] [Anticonceptivos hormonales, respuestas inmunológicas y enfermedad pélvica inflamatoria. Carta.]
  46. Hormonal contraception, immune responses, and pelvic inflammatory diseases. Authors' reply [letter]
  47. Husband-wife communication and family planning practices among Malay married couples in Mukim Rusila, Terengganu.
  48. The immune system and hormones: review and relevance to pregnancy and contraception in women with MS.
  49. The impact of using emergency contraception on reproductive health outcomes: a retrospective review in an urban adolescent clinic.
  50. Implanon: user views in the first year across three family planning services in the Trent Region, UK.
  51. Implantable contraceptives -- an overview.
  52. Implantable contraceptives -- an overview.
  53. Importance and knowledge of oral contraceptives in antepartum, low-income, African American adolescents.
  54. Improving demand-oriented quality care in family planning -- a review of practice and experience in family planning programme of Qianjiang, Hubei.
  55. Improving quality of care and use of contraceptives in Senegal. [Amélioration de la qualité des soins et du recours aux contraceptifs au Sénégal.]
  56. Improving young people's access to emergency contraception.
  57. Indigenous Systems of Medicine Practitioners (ISMP) contraceptive sales motivation in India.
  58. Influence of a new monophasic oral contraceptive on body metabolism. [Wplyw stosowania nowej, jednofazowej doustnej tabletki antykoncepcyjnej na metabolizm.]
  59. Information about contraception for young people.
  60. Information from adolescents about contraceptive methods. [Informaçoes dos adolescentes sobre métodos anticoncepcionais.]
  61. Informing choices: expanding access to emergency contraception in Peru. [Opciones disponibles: ampliación del acceso a la anticoncepción de emergencia en Perú.]
  62. Insurance coverage for reversible contraception. A legal battle for women and NPs.
  63. Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis.
  64. The interaction between St John's wort and an oral contraceptive.
  65. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.
  66. Interest in extended-use contraception to grow.
  67. Intrauterine contraception: most cost-effective birth control.
  68. Management of menstrual problems and contraception in adolescents with mental retardation: a medical, legal, and ethical review with new suggested guidelines.
  69. Maternal oral contraceptive use and atopic diseases in the offspring.
  70. Mechanisms of action of emergency contraception. [Mecanismos de acción en la anticoncepción de emergencia.]
  71. Medicaid family planning expansions hit stride.
  72. Medical and other noncontraceptive uses of combined oral contraceptives.
  73. Medication of the month. Evra: first contraceptive transdermal patch. [Le médicament du mois. Evra: premier patch pour la contraception transdermique.]
  74. Mesenteric vein thrombosis associated with intravaginal contraceptives: a case report and review of the literature.
  75. Mifepristone: a novel estrogen-free daily contraceptive pill.
  76. More than handing out contraceptives.
  77. More women know about emergency contraception, but can they get it? New Mexico, Hawaii latest states to offer pharmacist provision of EC.
  78. Multidetector CT appearance of a novel contraceptive device: the vaginal ring.
  79. Nestorone: clinical applications for contraception and HRT.
  80. New and emerging contraceptive methods.
  81. New approaches to contraception are needed.
  82. New contraceptive choices across reproductive life [letter]
  83. New contraceptive methods: counseling.
  84. New hormonal contraceptives: a comprehensive review of the literature.
  85. New options in contraception for teenagers.
  86. Nigeria. Baseline assessment of the contraceptive logistics system.
  87. Nigeria: assessment of the transportation system and distribution costs for family planning commodities.
  88. Non-contraceptive benefits of oral contraception. [Bénéfices non contraceptifs de la contraception orale.]
  89. Non-latex versus latex male condoms for contraception.
  90. Non-oral hormonal contraception.
  91. Nonmenstrual adverse events associated with subdermal contraceptive implants containing normegestrel and levonorgestrel.
  92. Norplant contraceptive implants. Evaluation of weight and blood pressure side effects in three family planning clinics in Dakar, Senegal. [Les implants contraceptifs Norplant. Evaluation des effets secondaires, du poids et de la tension arterielle dans 3 cliniques de planification familiale a Dakar (Senegal)]
  93. Oral contraception and cyclic changes in premenstrual and menstrual experiences.
  94. Oral contraception over the age of 40.
  95. Oral contraception.
  96. Oral contraceptive and smoking mortality [letter]
  97. Oral contraceptive and smoking mortality. Authors' reply [letter]
  98. Oral contraceptive practices among female medical students of the University of Warsaw. [Stosowanie doustnych srodkow antykoncepcyjnych wsrod studentek akademii medycznej w Warszawie.]
  99. Oral contraceptives and inherited thrombophilia: a gene-environment interaction with a risk of venous thrombosis?
  100. Oral contraceptives and reproductive system cancer.
  101. Oral contraceptives and the risk of ductal breast carcinoma in situ.
  102. Oral contraceptives and venous thromboembolic events [letter]
  103. Oral contraceptives: newer formulations and new data.
  104. Participation by clients and nurse midwives in family planning decision making in Indonesia.
  105. The patched polymorphism PRO1315LEU (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk.
  106. Patterns of contraceptive use at the edge of fertility transition in Zimbabwe. [Exemples de recours à des méthodes contraceptives au seuil du passage à la fertilité au Zimbabwe.]
  107. Perception of efficacy and safety as determinants for use and discontinuation of birth control methods in Muslim Jordanian women.
  108. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women.
  109. Permanent contraception for women in the United States.
  110. Pharmacogenetic aspects of the use of oral contraceptives and the risk of thrombosis.
  111. Pharmacy provision of emergency contraception: the Ontario emergency contraception pilot project.
  112. The Philippines: Introducing the Standard Days Method into a hospital-based family planning service.
  113. Policies needed to increase awareness of emergency contraception.
  114. Population Services International, Afghanistan. Focus group discussion summary of result. Birth spacing attitudes, experience and contraceptive branding among Afghan women. Final report.
  115. Praise for emergency contraception info [letter]
  116. Preparation and characterization of injectable microspheres of contraceptive hormones.
  117. Prescribing oral contraceptives for women older than 35 years of age. [Prescription de contraceptifs oraux pour femmes de plus de 35 ans.]
  118. Prescribing oral contraceptives: focusing on each woman as an individual case.
  119. Prevalence of lower genital tract infection among women attending maternal and child health and family planning clinics in Hanoi, Vietnam.
  120. Prevalence of pregnancy related oral granuloma in a Nigerian population group and the possible role of contraceptives.
  121. A profile of contraceptive non-use in Kuwait: implications for health and health care.
  122. Progestogen-only emergency contraception and ectopic pregnancy [editorial]
  123. Progestogens and breast cancer risk: the role of hormonal contraceptives and hormone replacement therapy.
  124. Projections for contraceptives, including condoms for HIV / AIDS in Nigeria. Determining needs and cost of contraceptives for Nigeria, 2003 - 2015.
  125. Prospective analysis of weight changes in adolescent females initiating depot medroxyprogesterone acetate (DMPA), oral contraceptive pills (OC), or no hormonal contraceptive method.
  126. Prospectively reported symptom change across the menstrual cycle in users and non-users of oral contraceptives.
  127. Protecting against unintended pregnancy: an overview of standard contraceptives.
  128. Protecting stored contraceptive commodities from pest damage.
  129. Providing subsidies and incentives for Norplant, sterilization and other contraception: allowing economic theory to inform ethical analysis.
  130. Pulmonary lymphangioleiomyomatosis (LAM): examining oral contraceptive pills and the onset of disease.
  131. Quality characteristics of field workers and contraceptive use dynamics: lessons from Matlab, Bangladesh.
  132. Questions and answers about transcervical sterilization: a new choice in permanent birth control.
  133. Questions for recommendations for clinical practice emergency contraception.
  134. Readers rank top oral contraceptives.
  135. Realizing reproductive choice and rights: abortion and contraception in India.
  136. Reasons for not using family planning methods in eastern Turkey.
  137. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy.
  138. Reducing the risk of pregnancy - the role of contraception.
  139. Reducing the risk of pregnancy - the role of contraception.
  140. Regulation of testicular function in men: implications for male hormonal contraceptive development.
  141. The relationship between attitudes toward pregnancy and contraception use among drug users.
  142. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. [Rapports entre les contraceptifs hormonaux stéroïdes et le VPH, la néoplasie inter-épithéliale et le carcinome cervical.]
  143. Relative risk of cervical cancer rises with duration of oral contraceptive use.
  144. Relieving the impacts of oral contraceptives on lipids profile by taking pills in a novel scheme.
  145. Report on field test of the WHO Decision-Making Tool (DMT) for family planning clients and providers in Mexico. Draft. [Informe sobre pruebas de campo de la Herramienta de toma de decisiones (DMT, Decision-Making Tool) de la OMS para los clientes y prestadores de planificación familiar en México. Versión preliminar.]
  146. Report on the field test of the WHO Decision-Making Tool (DMT) for family planning clients and providers in Indonesia. Draft.
  147. Reproductive and contraceptive characteristics of premenopausal kidney transplant recipients.
  148. Reproductive health including family planning.
  149. Reproductive knowledge, sexual behaviour and contraceptive use among adolescents in Niger State of Nigeria. [Connaissances en matière de reproduction, comportements sexuels et utilisation des modes contraceptifs parmi les adolescents dans l'état du Niger au Nigeria.]
  150. Researchers explore extended contraception.
  151. Results of the 2002 population change and family planning survey.
  152. A review of androgen-progestin regimens for male contraception.
  153. Risk of ischemic stroke among users of the oral contraceptive pill. The Melbourne Risk Factor Study (MERFS) Group.
  154. Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives.
  155. Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception.
  156. The role of men in family planning: an examination of men's knowledge and attitude to contraceptive use among the Yorubas. [Le rôle des hommes dans la planification familiale : une étude des connaissances et attitude des hommes face à l'utilisation de méthodes contraceptives chez les Yorubas.]
  157. The role of the pharmacist in emergency contraception [editorial]
  158. In search of appropriate contraception: horses for courses.
  159. Selection effects of source of contraceptive supply in an analysis of discontinuation of contraception: multilevel modelling when random effects are correlated with an explanatory variable.
  160. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception.
  161. Sex in Australia: contraceptive practices among a representative sample of women.
  162. Sexual health risks among young Thai women: implications for HIV / STD prevention and contraception.
  163. Sexually active women's beliefs in choosing or rejecting contraceptive methods. [Crenças de mulheres com vida sexual ativa na escolha ou nao de métodos contraceptivos.]
  164. Sexually transmitted infections and contraceptives: selective issues.
  165. Should a patient with a history of melanoma be advised against the use of oral contraceptives? The relatives are worried.
  166. Should endometrial hyperplasia be regarded as a reason for abnormal uterine bleeding in users of the intrauterine contraceptive device?
  167. Skin patch and vaginal ring versus combined oral contraceptives for contraception.
  168. The social amplification of risk and the hazard sequence: the October 1995 oral contraceptive pill scare.
  169. Socio-cultural deterrents to family planning practices among Swazi women.
  170. Socio-demographic profile of emergency contraceptive users.
  171. The standard days method: an innovative approach to family planning. [Método de los días fijos: un enfoque innovador para la planificación familiar.]
  172. Statement on new law mandating contraceptives coverage in group health plans.
  173. Status and future direction of male contraceptive development.
  174. Sterilization most widely used contraceptive method in world.
  175. Strategies to improve compliance and acceptability of hormonal methods of contraception.
  176. A study of the various contraceptive methods adopters in some states of India in 1990's.
  177. Substance misuse among women attending family planning clinics in a rural area in Britain: prevalence and associated problems.
  178. Targeting: an essential element of national contraceptive security planning.
  179. Time for Today sponge in Canada -- Will U.S. see vaginal contraceptive? Company is seeking FDA approval for marketing in United States.
  180. Transient ischaemic attack associated with the new contraceptive Yasmin [letter]
  181. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives.
  182. Trends in contraceptive effectiveness and birth rates among U.S. teens by parity, 1988 and 1995. [Tendances dans l'efficacité du contraceptif et taux de natalité chez les adolescents américains par parité, 1988 et 1995.]
  183. The truth about oral contraceptives and venous thromboembolism.
  184. Two pathways of progesterone action in the human endometrium: implications for implantation and contraception.
  185. Ultrasound detection of the Essure permanent birth control device: a case series.
  186. Uncertainty in estimating the day of ovulation causes overestimation of the role of ovulation disturbance on the effectiveness of the Yuzpe method of emergency contraception [letter]
  187. Unmet need for contraception in Kuwait: a developing country without a family planning program.
  188. Unmet need for contraception in northeastern states.
  189. Update on contraception: benefits and risks of the new formulations.
  190. Use of an oral contraceptive containing drospirenone in an extended regimen.
  191. Use of dydrogesterone as a progestogen for oral contraception.
  192. The use of family planning methods in an administrative district of Istanbul.
  193. Use of oral contraceptives blunts the calciuric effect of caffeine in young adult women. [Utilización de anticonceptivos orales atempera el efecto calciúrico de la cafeína en las adultas jóvenes.]
  194. Use of progestins in male contraception.
  195. Using financing to motivate a for-profit health care provider to deliver family planning services: is it a cost-effective intervention? A study of AAR health services in Kenya.
  196. Uterovesical fistula and bladder stones following bladder penetration by a perforating intrauterine contraceptive device.
  197. Vaginal contraception: new form of administration of hormonal contraception. [Vaginale anticonceptie: hormonale anticonceptie in een andere toedieningsvorm.]
  198. Venous thromboembolism and combined oral contraceptives. Reported adverse reactions indicate at least similar risk with the most recent contraceptive pills. [Venos tromboembolism och kombinerade p-piller. Biverkningsrapporter talar for minst lika stor risk med de nyaste p-pillren.]
  199. Vesical stone formation around a partially migrated intrauterine contraceptive device.
  200. Vulnerable women need family planning access.
  201. Women's knowledge and opinions of emergency contraception.
  202. Women, family, and reproductive health: a case study on family planning on the outskirts of Recife, Pernambuco, Brazil. [Mulher, familia e reproduçao: um estudo de caso sobre o planejamento familiar em periferia do Recife, Pernambuco, Brasil.]
  203. Younger Catholics embrace traditions. Going against the flow on the subject of birth control?
  204. Will Australian men use male hormonal contraception? A survey of a postpartum population.
  205. Contraceptive use among U.S. women having abortions in 2000-2001.
  206. Chronically homeless women's perceived deterrents to contraception.
  207. Factors affecting British teenagers' contraceptive use at first intercourse: the importance of partner communication.
  208. Predictors of contraceptive discontinuation in a sexually transmitted disease clinic population.
  209. Contraceptive method switching in the United States.
  210. U.S. agencies providing publicly funded contraceptive services in 1999.
  211. The trade-off between hormonal contraceptives and condoms among adolescents.
  212. Unmet need for contraception in the developing world and the former Soviet Union: an updated estimate.
  213. Fertility regulation among women in Abidjan, Cote d'Ivoire: contraception, abortion or both? [Régulation de la fertilité des femmes à Abidjan, Côte d'Ivoire : contraception, avortement ou les deux ?]
  214. Source of maternal and child health care as an indicator of ability to pay for family planning. [Origen de la atención de la salud materno infantil como indicador de la capacidad de pago por los servicios de planificación familiar.]
  215. Dual needs: contraceptive and sexually transmitted infection protection in Lusaka, Zambia.
  216. Promoting dual protection in family planning clinics in Ibadan, Nigeria.
  217. Integration of STI prevention and management with family planning and antenatal care in sub-Saharan Africa -- What more do we need to know?
  218. Excess capacity and the cost of adding services at family planning clinics in Zimbabwe.
  219. Contraceptive method choice in developing countries.
  220. Spousal communication and family planning adoption: effects of a radio drama serial in Nepal.
  221. Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception.

     

  222. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
  223. Improving teenagers' knowledge of emergency contraception: cluster randomised controlled trial of a teacher led intervention.
  224. Young women's accounts of factors influencing their use and non-use of emergency contraception: in-depth interview study.
  225. Mechanisms that explain the contraceptive action of progestin implants for women.
  226. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception.
  227. Metabolic effects of implantable steroid contraceptives for women.
  228. Methodological quality of WHO medical eligibility criteria for contraceptive use.
  229. Migrant fathers and their attitudes to potential male hormonal contraceptives.
  230. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies.
  231. Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception : results of a French clinical study in women aged 35 to 45 years. [Acceptabilité du système intra-utérin de déversement du lévonorgestrel après interruption d'une méthode contraceptive précédente : résultats d'une étude clinique française de femmes âgées de 35 à 45 ans.]
  232. Acceptance of altering the standard 21-day / 7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms.
  233. Access as a factor in differential contraceptive use between Mayans and ladinos in Guatemala. [Acceso como factor en el uso diferenciado de anticonceptivos entre los Mayas y latinos en Guatemala.]
  234. Adolescent compliance and side effects with Quick Start initiation of oral contraceptive pills. [Respect du traitement par les adolescents et effets secondaires avec l'introduction par la Quick Start des pilules contraceptives orales.]
  235. Adolescents' ambivalence about becoming pregnant predicts infrequent contraceptive use: a prospective analysis of nonpregnant African American females.
  236. Advance provision of oral contraceptives to family planning clients in Kenya.
  237. Africa: the new family planning frontier.
  238. Antecedents of adolescent initiation of sex, contraceptive use, and pregnancy.
  239. Asia's family planning programs as low fertility is attained.
  240. Assessment of a new approach to family planning services in rural Pakistan.
  241. Assessment of compliance with a weekly contraceptive patch (Ortho Evra / Evra) among North American women.
  242. Assessment of human sperm function after hydrogen peroxide exposure: development of a vaginal contraceptive.
  243. Attitudes of mothers toward their daughters' use of contraceptives in Israel.
  244. Barriers to use of oral contraceptives in ethnic Chinese women presenting for abortions.
  245. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception.
  246. Bone mineral density in adolescent and young Thai girls receiving oral contraceptives compared with depot medroxyprogesterone acetate: a cross-sectional study in young Thai women.
  247. The campaign against contraception in Latin America -- the case of Argentina. [Campaña contra la anticoncepción en América Latina: el caso de Argentina.]
  248. Cervical mucus granulocyte macrophage colony stimulating factor and interleukin-2 soluble receptor in women using copper intrauterine contraceptive devices.
  249. China's family planning policy: an overview of its past and future.
  250. Clinical comparative study of oral contraceptives containing 30 micrograms ethinylestradiol / 150 micrograms levonorgestrel, and 35 micrograms ethinylestradiol / 250 micrograms norgestimate in Thai women.
  251. Clinical Pearls: factors affecting reported contraceptive efficacy rates in clinical studies.
  252. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report.
  253. Clinical performance of the Nova T380 intrauterine device in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report.
  254. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra / Evra)
  255. Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians.
  256. Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route.
  257. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel / ethinyl estradiol.
  258. A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 micrograms ethinylestradiol / 75 micrograms gestodene (Meliane) and 30 micrograms ethinylestradiol / 75 micrograms gestodene (Gynera)
  259. Consensus statement on intrauterine contraception.
  260. The construction of community participation: village family planning groups and the Indonesian state.
  261. Contraception and induced abortion in rural Ghana.
  262. Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study.
  263. Contraception and unexplained abdominal pain. [Contraception et douleurs abdominales inexpliquées.]
  264. Contraception for women in selected circumstances.
  265. Contraceptive efficacy and cycle control with the Ortho Evra / Evra transdermal system: the analysis of pooled data.
  266. Contraceptive failure -- results from a study conducted among women with accepted and unaccepted pregnancies in Denmark.
  267. Contraceptive failure in China.
  268. Contraceptive implants and lactation.
  269. Contraceptive implants: single-rod Implanon headed to United States.
  270. Contraceptives and cerebral thrombosis: a five-year national case-control study.
  271. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days.
  272. Declining fertility among North American Hutterites: the use of birth control within a Dariusleut colony.
  273. Determinants for non-use of contraception at first intercourse; a study of 10,841 young Danish women from the general population.
  274. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII.
  275. Does contraceptive method change the Pap smear finding?
  276. Dual protection against unintended pregnancy and sexually transmitted infections. What is the best contraceptive approach?
  277. Ectopic pregnancy risk when contraception fails. A review.
  278. Effect of a new injectable male contraceptive on the seminal plasma amino acids studied by proton NMR spectroscopy.
  279. The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol: a randomized placebo controlled trial.
  280. Effect of dienogest-containing oral contraceptives on lipid metabolism.
  281. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. [Effet des contraceptifs oraux sur le risque de cancer du col de l'utérus chez les femmes souffrant de papillomavirus humain : étude multi-centrée de contrôle de l'IARC; [Efecto de los anticonceptivos orales sobre el riesgo de cáncer cervical en mujeres con infección por papilomavirus humano: estudio multicéntrico de control de casos del Centro Internacional de Investigaciones sobre el Cáncer (IARC)]
  282. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations.
  283. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa.
  284. Efficacy of a new method of family planning: the Standard Days Method. [Eficacia de un nuevo método de planificación familiar: el Método de Días estándar.]
  285. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring.
  286. The elimination of contraceptive acceptor targets and the evolution of population policy in India.
  287. Emergency contraception among teenagers in Switzerland: a cross-sectional survey on the sexuality of 16- to 20-year-olds.
  288. Emergency contraception among university students in Kingston, Jamaica: a survey of knowledge, attitudes, and practices.
  289. Emergency contraception in Mexico City: knowledge, attitudes, and practices among providers and potential clients after a 3-year introduction effort. [Anticoncepción de emergencia en la ciudad de México: conocimientos, actitudes y prácticas entre prestadores y clientes potenciales después de un esfuerzo introductorio de 3 años.]
  290. Emergency contraception with mifepristone and levonorgestrel: mechanism of action.
  291. Emergency contraception: knowledge and use among Danish women requesting termination of pregnancy.
  292. Emergency oral contraception. ACOG Practice Bulletin, No. 25, March 2001.
  293. Estimating the efficacy of emergency contraception -- how reliable are the data?
  294. Evaluation of an emergency contraception introduction project in Kenya.
  295. Expanding contraceptive choice in Ethiopia.
  296. Experience with GyneFIX insertions in Spain: favorable acceptance of the intrauterine contraceptive implant with some limitations.
  297. Factors affecting ever-married men's contraceptive knowledge and use in Nigeria.
  298. Factors in contraceptive method choice in Bangladesh: goals, competence, evaluation and access.
  299. Family history of cancer, oral contraceptive use, and ovarian cancer risk.
  300. Fertilisation and implantation failure in an oral contraceptive user.
  301. The future of family planning programs.
  302. Future trends in contraceptive prevalence and method mix in the developing world.
  303. Gender preference, contraceptive use and fertility in India: regional and development influences.
  304. Get ready to add new contraceptive options.
  305. Gossypol: a contraceptive for men. [Gossypol: anticonceptivo para hombres.]
  306. Has the Chinese family planning policy been successful in changing fertility preferences?
  307. Health and growth of infants breastfed by Norplant contraceptive implants users: a six-year follow-up study. [Salud y crecimiento de los neonatos amamantados por usuarias del implante anticonceptivo Norplant: estudio de seguimiento a seis años.]
  308. Health services at the clinic level and implantable contraceptives for women. [Services de santé au niveau de la clinique et contraceptifs à implanter pour les femmes.]
  309. The hide-and-seek game: men's perspectives on abortion and contraceptive use within marriage in a rural community in Zimbabwe.
  310. HIV infection in women: impact on contraception. [Infección por VIH en las mujeres: impacto sobre la anticoncepción.]
  311. Husbands, wives, sons, and daughters: fertility preferences and the demand for contraception in Ethiopia.
  312. Hysteroscopic tubal sterilization with the Essure nonincisional permanent contraception system.
  313. The impact of government policies and neighborhood characteristics on teenage sexual activity and contraceptive use.
  314. The impact of price changes on demand for family planning and reproductive health services in Ecuador. [Impacto de los cambios de precio sobre la demanda de servicios de planificación familiar y salud reproductiva en Ecuador.]
  315. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies.
  316. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen.
  317. Inconsistent use of oral contraceptives in rural Bangladesh.
  318. Indazole carboxylic acids in male contraception.
  319. Indirect exposure to a family planning mass media campaign in Nepal.
  320. Influence of low-dose oral contraception on peripheral blood lymphocyte subsets at particular phases of the hormonal cycle.
  321. Information campaign and advocacy efforts to promote access to emergency contraception in Mexico. [Campaña de información y esfuerzos en pro de la promoción del acceso a la anticoncepción de emergencia en México.]
  322. Integrated summary of Ortho Evra / Evra contraceptive patch adhesion in varied climates and conditions.
  323. Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone.
  324. Is "abortion culture" fading in the former Soviet Union? Views about abortion and contraception in Kazakhstan.
  325. Is postpartum contraceptive advice given antenatally of value?
  326. Knowledge about contraception in women undergoing repeat voluntary abortions, and means of prevention.
  327. Knowledge, use and attitudes towards emergency contraceptive pills among Swedish women presenting for induced abortion.
  328. Long-term effects of combined oral contraceptives on markers of endothelial function and lipids in healthy premenopausal women.
  329. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.
  330. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
  331. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials.
  332. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs.
  333. Official warnings on thromboembolism risk with oral contraceptives fail to inform users adequately.
  334. Oral contraception and epilepsy: findings in a large cohort study.
  335. Oral contraception: trends over time.
  336. Oral contraceptive use and exercise-induced muscle damage and recovery.
  337. Oral contraceptive use by teenage women does not affect body composition.
  338. Oral contraceptives and risk of gestational trophoblastic disease.
  339. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study.
  340. Oral contraceptives and venous thromboembolism: a five-year national case-control study.
  341. Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis. [Los anticonceptivos orales suprimen la proliferación celular y aumentan la apoptosis del tejido endometrial eutópico de las pacientes con endometriosis.]
  342. Ovarian function with a novel combined contraceptive vaginal ring.
  343. Oves contraceptive cap: short-term acceptability, aspects of use and user satisfaction.
  344. Perception of university students in Ghana about emergency contraception.
  345. Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women.
  346. Policy climate, scholarship, and provision of emergency contraception at affiliates of the International Planned Parenthood Federation in Latin America and the Caribbean.
  347. Predicting risk of ovulation in new start oral contraceptive users.
  348. The prevalent use of contraception among teenagers in Denmark and the corresponding low pregnancy rate.
  349. Prevention of migraine in the pill-free interval of combined oral contraceptives: a double-blind, placebo-controlled pilot study using natural oestrogen supplements.
  350. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive.
  351. Progestin implants for female contraception.
  352. Prolonged use of oral contraception before a planned pregnancy is associated with a decreased risk of delayed conception.
  353. Provision of Chlamydia trachomatis screening in family planning clinics and emergency contraception in genitourinary medicine clinics: a collaborative cross-speciality survey.
  354. The provision of family planning services in the Caribbean.
  355. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.
  356. Quality, mainstream services with proactive and targeted outreach: a model of contraceptive service provision for young people.
  357. Quick Start: a novel oral contraceptive initiation method.
  358. Race, adolescent contraceptive choice, and pregnancy at presentation to a family planning clinic.
  359. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism.
  360. A randomized double-blind comparison of two single doses of mifepristone for emergency contraception.
  361. Reasons for using traditional methods and role of nurses in family planning.
  362. Recent advances in hormonal male contraception.
  363. Recent developments in contraceptive implants at the Population Council.
  364. Reconsidering the doorstep-delivery system in the Bangladesh family planning program.
  365. The relevance of client-centered communication to family planning settings in developing countries: lessons from the Egyptian experience.
  366. Revisiting a pilot survey involving contraception and teenage pregnancy in Ayrshire and Arran.
  367. The risk of breast tumours and lifetime history of oral contraceptive use.
  368. Safety and efficacy of a new oral contraceptive containing drospirenone.
  369. Safety of implantable contraceptives for women : data from observational studies. [Sécurité des contraceptifs à implanter pour les femmes : données d'études d'observation.]
  370. Scanning electron microscopic (SEM) changes of the endometrium in women taking high doses of levonorgestrel as emergency postcoital contraception.
  371. Screening for Chlamydia trachomatis infection is indicated for women under 30 using emergency contraception.
  372. Screening for genital Chlamydia trachomatis in teenagers attending a family planning youth clinic: a prevalence study using a strand displacement assay on urine samples.
  373. Sex behavior among high school students in Sweden: improvement in contraceptive use over time.
  374. Sex, contraception and contradiction among young Filipinas in Australia.
  375. Shouldn't all victims of sexual assault be offered emergency contraception?
  376. Simultaneity in the use of maternal-child health care and contraceptives: evidence from developing countries. [Utilisation simultanée des soins de santé maternelle et infantile et des contraceptifs : les pays en développement; [Simultaneidad en el uso de la atención materno infantil y de anticonceptivos: evidencia de los países en desarrollo.]
  377. The Standard Days Method: a new method of family planning.
  378. Study of bias in antenatal clinic HIV-1 surveillance data in a high contraceptive prevalence population in sub-Saharan Africa.
  379. A study on the knowledge and practice of contraception among men in the United Arab Emirates.
  380. Supply-level measures to increase uptake of family planning services in Niger : the effectiveness of improving responsiveness. [Mesures au niveau de l'offre en vue d'accroître l'assimilation des services de planning familial au Niger : efficacité de l'amélioration de la réceptivité.]
  381. Surface vascularization and endometrial appearance in women with menorrhagia or using levonorgestrel contraceptive implants. Implications for the mechanisms of breakthrough bleeding.
  382. Termination of pregnancy following panic-stopping of oral contraceptives.
  383. Toxicology of polymers for implant contraceptives for women.
  384. Toxicology of progestogens of implantable contraceptives for women.
  385. Transdermal contraception: evaluation of three transdermal norelgestromin / ethinyl estradiol doses in a randomized, multicenter, dose-response study.
  386. The transdermal contraceptive patch: a new approach to hormonal contraception.
  387. Transforming family planning services in the Latin American and Caribbean region. [Transformación de los servicios de planificación familiar en América Latina y la región del Caribe.]

     

  388. Triphasic oral contraceptives: review and comparison of various regimens.
  389. The use of induced abortion as a contraceptive : the case of Mongolia. [Utilisation de l'avortement provoqué comme contraceptif : cas de la Mongolie.]
  390. Use of mandelic acid condensation polymer (SAMMA), a new antimicrobial contraceptive agent, for vaginal prophylaxis.
  391. Use of MRI to determine the in vivo position of a silicone vaginal barrier contraceptive device.
  392. Use of progestogen-only contraceptives / medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian survey.
  393. Users' perspectives on implantable contraceptives for women.
  394. Using a low-dose contraceptive in women 35 years of age and over: 20 micrograms estradiol / 100 micrograms levonorgestrel.
  395. Vaginal bleeding disturbances and implantable contraceptives. [Problèmes de saignements vaginaux et contraceptifs à implanter.]
  396. Vaginal wetness: an underestimated problem experienced by progestogen injectable contraceptive users in South Africa.
  397. What do women want? The answer is simple : convenient birth control. [Que veulent les femmes ? La réponse est simple : un bon contrôle des naissances.]
  398. Women's voices about emergency contraceptive pills "over-the-counter": a Swedish perspective.
  399. Making decisions about contraceptive introduction: a guide for conducting assessments to broaden contraceptive choice and improve quality of care.
  400. Cervical cancer, oral contraceptives and parity.
  401. U.S. defends family planning policies at Bangkok conference.
  402. Single-dose emergency contraception works.
  403. Impact of a male motivation campaign on family planning ideation and practice in Guinea. PRISM project. [Impact d'une campagne de sensibilisation masculine envers le concept et la pratique du planning familial en Guinée. Le projet PRISM (Pour Renforcer les Interventions en Santé Reproductive et MST/SIDA)]
  404. Uso de métodos anticoncepcionais e adequaçao de contraceptivos hormonais orais na cidade de Pelotas, Rio Grande do Sul, Brasil: 1992 e 1999. [Contraceptive method use and adequacy of oral contraceptive use in the city of Pelotas, Rio Grande do Sul, Brazil: 1992 and 1999.]
  405. Scientists find lemon juice is an effective contraceptive.
  406. U.N.: Family planning spurs growth in poor nations.
  407. Cost-effectiveness of self-assessment and peer review in improving family planning provider-client communication in Indonesia.
  408. PSI boosts contraceptive, malarial protection in 2001.
  409. PSI spearheads nationwide family planning partnership in Guinea. [En Guinée le PSI est à la pointe du partenariat au niveau national en matière de planning familial.]
  410. Kenya. Linking family planning with postabortion care.
  411. Dominican Republic: consumer-driven quality. Using client input to improve services. Assistance to a family planning NGO. Results review. [República Dominicana: calidad orientada por el consumidor. Utilización de los comentarios de los clientes para mejorar los servicios. Asistencia a una ONG de planificación familiar. Reseña de resultados.]
  412. Dominican Republic: responsive training and learning. Comparing learning approaches. Community health promoters for family planning and preventive services. Results review. [República Dominicana: capacitación y aprendizaje receptivos. Comparación de enfoques de aprendizaje. Promotores de salud comunitaria para la planificación familiar y los servicios de prevención. Reseña de resultados.]
  413. Sterilization world's no. 1 contraceptive method.
  414. Securing future supplies for family planning and HIV / AIDS prevention.
  415. More contraceptives can save lives, UNFPA report says.
  416. U.N. data show two-thirds of world's couples use contraception.
  417. Planning and managing contraceptive phaseout. Applying lessons learned. [Planification et gestion de l'arrêt de la contraception. Application des leçons apprises; [Planificación y manejo de la retirada progresiva de anticoncepción. Aplicación de las lecciones aprendidas.]
  418. Friends strongly influence contraceptive use in Ghana.
  419. Altering cell bonds in testis may yield contraceptive.
  420. Peer education as a strategy to increase contraceptive prevalence and reduce the rate of STIs / HIV among adolescents in Cameroon. [L'éducation par les pairs comme stratégie d'accroissement de la prévalence contraceptive et de réduction du taux d'IST/VIH chez les adolescents du Cameroun.]
  421. Contraceptive self reliance through financial sustainability: a market segmentation approach. Executive summary.
  422. Contraceptive self reliance through financial sustainability: a market segmentation approach.
  423. China succeeded in family planning, ratio of minors drops by big margin.
  424. Comprehensive reproductive health and family planning training curriculum. Module 16: Reproductive health services for adolescents. Participant's manual.
  425. Michigan: Cuts in Planned Parenthood financing.
  426. After long hiatus, new contraceptives emerge.
  427. At U.N. family-planning talks, U.S. raises abortion issue.
  428. Beyond birth control: the pill tackles new duties. [Au-delà du contrôle des naissances : la pilule s'attaque à de nouvelles tâches.]
  429. Birth control is changing, and its price is rising.
  430. Birth control politics [editorial]
  431. Bush family-planning policy criticized.
  432. Girls link their use of family planning clinics to keeping parents in the dark.
  433. Implacable force for family planning.
  434. Over U.S. protest, Asian group approves family planning goals.
  435. U.S. to withhold family-planning money from U.N.
  436. Women tout contraception bill.
  437. Schering and Organon developing male hormonal contraceptive for U.S. and European markets.
  438. Men's contraceptive options slowly improve.
  439. Expanding access to family planning through MEDICAID.
  440. Women in MEDICAID managed care deserve full information about their right to family planning services.
  441. The decline in teen pregnancy rates: a result of abstinence and contraception, not abstinence-only programs.
  442. A hormonal male contraceptive: from wish to reality [editorial]
  443. Risk of taking oral contraceptives in patients with a history of migraine with neurological signs.
  444. Menstrual and contraceptive management in women with an intellectual disability.
  445. Attitudes toward family planning and reasons for nonuse among women with unmet need for family planning in Ethiopia.
  446. Contraception-abortion connections in Armenia.
  447. More LGUs turn to vasectomy as family planning method.
  448. Contraceptive use and methods in the U.S. Facts.
  449. Hormonal contraception forty years after approval of "the pill". Update.
  450. Wall Street Journal examines oral contraceptive Yasmin's reputation as weight-loss aid.
  451. Attitudes of family planning workers on the provision of sexual and reproductive health services to unmarried young adults in China.
  452. Fertility trends and the prospect of family planning program in China: its future changes and related policy selection.
  453. Economic decline, contraceptive use, and willingness to abort.
  454. New law to provide for free birth control.
  455. How gender-sensitive are your HIV and family planning services? Use IPPF / WHR's HIV / Gender Continuum to find out.
  456. Learning from the field: experiences in HIV prevention from family planning associations worldwide.
  457. Corporate sector in India launches plan on health and family planning.
  458. Planned Parenthood Federation of Thailand addresses domestic violence.
  459. The growing medicalization of contraception in France. [La medicalisation croissante de la contraception en France.]
  460. Oral contraceptives.
  461. Barriers to implementing contraceptive security policies in Romania.
  462. Acceptability of reversible contraceptive methods. [Grado de aceptación de los métodos anticonceptivos reversibles.]
  463. Acceptability of reversible contraceptive methods. [Grado de aceptación de los métodos anticonceptivos reversibles.]
  464. Follow-up to the National Health and Demographic Survey: women's economic activities, fertility and contraceptive use. [Seguimiento a la Encuesta Nacional de Demografía y Salud: actividades económicas, fertilidad y uso de anticonceptivos de las mujeres.]
  465. Increase in acceptance rates for modern family planning methods. [Aumento en los índices de aceptación de los métodos modernos de planificación familiar.]
  466. Increasing contraceptive use in Bangladesh: the role of costs.
  467. Knowledge, attitudes and practices regarding family planning, sexually transmitted diseases, and infantile diarrhea in the city of El Alto (Districts I and II) [Conocimientos, actitudes y prácticas con respecto a la planificación familiar, enfermedades de transmisión sexual y diarrea infantil en la ciudad de El Alto (Barrios I y II)]
  468. Assessing the cost-effectiveness of contraceptive methods in Shiraz, Islamic Republic of Iran.
  469. Promoting family planning in a tribal community.
  470. The impact of a reproductive health project interventions on contraceptive use in Uganda.
  471. Overview of contraceptive and condom shipments, FY 2001.
  472. Engaging the private sector in Turkey. Can public / private partnerships help achieve contraceptive security?
  473. Pathways to contraceptive security. Workshop report.
  474. Large US study finds no link between oral contraceptives and breast cancer.
  475. Public funding and private insurance coverage for contraception.
  476. Transdermal contraceptive patch: efficacy in heavier women.
  477. How much is enough? Estimating requirements for subsidized contraceptives: results from a ten-country analysis.
  478. What influences the private provision of contraceptives? [Influencias del suministro privado de anticonceptivos.]
  479. Contraceptive security in Armenia: segmenting the family planning market.
  480. Delivery of private sector health care in Morocco. Attitudes and characteristics concerning family planning. [Prestataires des soins de sante du secteur prive au Maroc. Attitudes et caracteristiques en matiere de planification familiale.]
  481. The difference between emergency contraception and mifepristone (RU-486)
  482. China encourages NGOs to join family planning work.
  483. Family planning law and China's birth control situation.
  484. Menstrual nirvana: amenorrhea through the use of continuous oral contraceptives.
  485. Male contraception.
  486. Oral contraceptive use before first birth and risk of breast cancer: a case control study.
  487. A clinician's guide to levonorgestrel intrauterine contraception. Guide to inserting the LNG IUS.
  488. Current contraceptive research.
  489. How can pharmacies improve access to emergency contraception?
  490. The checkered history and bright future of intrauterine contraception in the United States.
  491. Accessibility and use of contraceptives in Vietnam.
  492. In search of seamless transition to post-lactational amenorrhea method contraception.
  493. Reproductive choices for Asian adolescents: a focus on contraceptive behavior.
  494. As desired fertility falls, contraceptive services help women avoid abortions.
  495. Emergency contraception is little known and rarely used by South Africans.